论文部分内容阅读
目的:筛选一种具有增强热休克融合蛋白HSP-MUC1抗肿瘤作用的免疫佐剂。方法:将HSP-MUC1与新型CpG ODN或人源性IFNα2b混合后皮下注射MUC1阳性荷瘤小鼠,各分4组,分别是磷酸盐缓冲液(PBS)、HSP-MUC1、CpG ODN(hIFNα2b)及HSP-MUC1+CpG ODN(HSP-MUC1+hIFNα2b)。观察各组肿瘤发生率及肿瘤体积变化。结果:HSP-MUC1+CpG ODN组与PBS组及HSP-MUC1组比较小鼠的肿瘤发生率及肿瘤重量均降低(P<0.05);单独应用CpG ODN组表现出与HSP-MUC1+CpG ODN组相似的抑瘤作用,与PBS组及HSP-MUC1组比较,肿瘤发生率及肿瘤的重量均降低(P<0.05);而HSP-MUC1+IFNα2b组与PBS组及HSP-MUC1组比较,小鼠肿瘤发生率及肿瘤重量差异均无显著性(P>0.05)。结论:CpG ODN是一种能增强HSP-MUC1抗肿瘤作用的免疫佐剂,人源性IFNα2b则不能增强HSP-MUC1的抗肿瘤活性。
Objective: To screen an immune adjuvant that has the anti-tumor effect of heat shock fusion protein HSP-MUC1. Methods: MUC1-positive tumor-bearing mice were subcutaneously injected with HSP-MUC1 and new CpG ODN or human IFNα2b. The mice were divided into 4 groups: PBS, HSP-MUC1, CpG ODN (hIFNα2b) And HSP-MUC1 + CpG ODN (HSP-MUC1 + hIFNα2b). The incidence of tumor and tumor volume in each group were observed. Results: Compared with PBS group and HSP-MUC1 group, the incidence of tumor and the tumor weight of mice in HSP-MUC1 + CpG ODN group decreased (P <0.05). Compared with HSP-MUC1 + CpG ODN group (P <0.05). Compared with PBS group and HSP-MUC1 group, the incidence of tumor and the weight of tumor in HSP-MUC1 + IFNα2b group were lower than those in PBS group and HSP-MUC1 group There was no significant difference in tumor incidence and tumor weight (P> 0.05). CONCLUSION: CpG ODN is an immune adjuvant that enhances the anti-tumor effect of HSP-MUC1. Human IFNα2b can not enhance the anti-tumor activity of HSP-MUC1.